Braden G A, Xenopoulos N P, Young T, Utley L, Kutcher M A, Applegate R J
Section of Cardiology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27157-1045, USA.
J Am Coll Cardiol. 1997 Sep;30(3):657-63. doi: 10.1016/s0735-1097(97)00215-5.
The purpose of this study was to evaluate the effectiveness of transluminal extraction catheter (TEC) atherectomy followed by immediate Palmaz-Schatz coronary stenting of coronary bypass vein grafts.
Degeneration of saphenous vein coronary bypass grafts has become a common problem. Repeat bypass surgery is associated with greater risk and a poorer outcome than the initial operation. Moreover, percutaneous interventional procedures in vein grafts have been associated with high procedural complication rates, including distal embolization, and high restenosis rates. TEC atherectomy may reduce distal embolization, and stenting may reduce restenosis rates.
We evaluated the procedural, hospital and clinical outcomes of TEC atherectomy followed by immediate Palmaz-Schatz coronary stenting of 53 vein grafts in 49 consecutive patients. The strategy was to limit instrumentation to extraction debulking and to stabilizing the site with stent deployment before using balloon dilation for optimal gain in lumen diameter.
Results are shown as mean value (95% confidence interval [CI]). The mean graft age was 9.2 years (95% CI 7.9 to 10.5), and 1.0 (95% CI 1 to 1) TEC cutter (2.2 mm [95% CI 2.1 to 2.3]) and 1.7 (95% CI 1.4 to 2.0) Palmaz-Schatz coronary stents/ vein graft were used. The procedural success rate was 98%, with a minimal lumen diameter at baseline of 1.3 mm (95% CI 1.1 to 1.5), increasing to 3.9 mm (95% CI 3.6 to 4.2) (p < 0.05) after the TEC-stent procedure. Procedural complications occurred infrequently: graft perforation in 1 (2%) of 53 patients and distal embolization in 1 (2%) of 53 (same patient). In-hospital complications included non-Q wave myocardial infarction in two patients and death after a successful procedure in three (6%) (n = 1 each: massive bleeding from the catheter site; sepsis; and acute myocardial infarction with asystole in the distribution of the stented vessel). The event-free survival rate to hospital discharge was 90%. Clinical follow-up (13 months [95% CI 11 to 15]) was available for all patients. There were five (11%) revascularization procedures (three bypass grafts and two percutaneous transluminal coronary interventions), four (9%) nonfatal myocardial infarctions and five (11%) deaths, for a cumulative rate of 28% for any adverse outcome occurring in 13 of 46 patients.
TEC atherectomy followed by immediate Palmaz-Schatz coronary stenting of stenoses in old (> 9 years) saphenous vein grafts can be successfully performed, with a low incidence of procedural and hospital complications. Clinical restenosis rates are low and less than those previously reported; however, late morbid cardiac events are still frequent in this high risk group of patients. These observational findings suggest that this technique may improve percutaneous management of vein graft disease, but optimal long-term management strategies remain to be determined.
本研究旨在评估腔内旋切抽吸导管(TEC)斑块旋切术联合即刻对冠状动脉搭桥静脉移植物进行Palmaz-Schatz冠状动脉支架置入术的有效性。
大隐静脉冠状动脉搭桥移植物的退变已成为一个常见问题。再次搭桥手术与比初次手术更大的风险和更差的预后相关。此外,静脉移植物的经皮介入操作与高手术并发症发生率相关,包括远端栓塞,以及高再狭窄率。TEC斑块旋切术可能减少远端栓塞,而支架置入术可能降低再狭窄率。
我们评估了49例连续患者中53条静脉移植物先进行TEC斑块旋切术,然后即刻进行Palmaz-Schatz冠状动脉支架置入术的手术、住院及临床结局。策略是将器械操作限于旋切减容,并在使用球囊扩张以获得最佳管腔直径增益之前,通过支架置入稳定手术部位。
结果以平均值(95%置信区间[CI])表示。移植物平均年龄为9.2岁(95%CI 7.9至10.5),使用了1.0(95%CI 1至1)个TEC切割器(2.2mm[95%CI 2.1至2.3])以及1.7(95%CI 1.4至2.0)个Palmaz-Schatz冠状动脉支架/静脉移植物。手术成功率为98%,基线时最小管腔直径为1.3mm(95%CI 1.1至1.5),在TEC-支架手术后增至3.9mm(95%CI 3.6至4.2)(p<0.05)。手术并发症发生率低:53例患者中有1例(2%)发生移植物穿孔,53例中有1例(2%)发生远端栓塞(为同一患者)。住院并发症包括2例患者发生非Q波心肌梗死,3例(6%)在成功手术后死亡(n=1例各为:导管部位大量出血;脓毒症;以及支架置入血管供血区急性心肌梗死伴心搏停止)。出院时无事件生存率为90%。所有患者均有临床随访(13个月[95%CI 11至15])。有5例(11%)血管重建术(3例搭桥移植物和2例经皮冠状动脉腔内介入治疗),4例(9%)非致命性心肌梗死和5例(11%)死亡,46例患者中有13例发生任何不良结局的累积发生率为28%。
对陈旧性(>9年)大隐静脉移植物狭窄先进行TEC斑块旋切术,然后即刻进行Palmaz-Schatz冠状动脉支架置入术可成功实施,手术及住院并发症发生率低。临床再狭窄率低,低于先前报道;然而,在这一高危患者群体中晚期心脏不良事件仍然频发。这些观察结果表明,该技术可能改善静脉移植物疾病的经皮治疗,但最佳长期治疗策略仍有待确定。